Determination of 10-chloromethyl-11-demethyl-12-oxo-calanolide A in rat plasma using liquid chromatography-tandem mass spectrometry and its application to pharmacokinetics

Biomed Chromatogr. 2014 Dec;28(12):1589-91. doi: 10.1002/bmc.3196. Epub 2014 Apr 24.

Abstract

A rapid and specific liquid chromatography-tandem mass spectrometry for the quantitation of 10-chloromethyl-11-demethyl-12-oxo-calanolide A (F18), a small-molecule nonnucleoside reverse transcriptase inhibitor, was developed and validated in rat plasma. F18 was monitored by positive electrospray ionization in the selected reaction monitoring mode. The standard curve was linear over the range of 2-1000 ng/mL. The method was used to determine the plasma concentration of F18 after a single oral dose of 50 mg/kg in rats.

Keywords: 10-chloromethyl-11-demethyl-12-oxo-calanolide A; LC-MS/MS; pharmacokinetics; quantitative determination; rat plasma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Chromatography, Liquid / methods*
  • Female
  • Male
  • Pyranocoumarins / blood*
  • Pyranocoumarins / chemistry
  • Pyranocoumarins / pharmacokinetics*
  • Rats
  • Rats, Wistar
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Spectrometry, Mass, Electrospray Ionization
  • Tandem Mass Spectrometry / methods*

Substances

  • 10-chloromethyl-11-demethyl-12-oxocalanolide A
  • Pyranocoumarins